Sass JO, Gemperle-Britschgi C, Tarailo-Graovac M, Patel N, Walter M, Jordanova A, Alfadhel M, Baric I, Coker M, Damli-Huber A, et al
Semaglutide medical weight loss is a medical treatment, clinical oversight and patient safety are essential components of care
The FLOW trial (Perkovic et al., New England Journal of Medicine , 2024) specifically studied semaglutide in CKD patients and found no need for dose adjustment
P.Dos SantosC
Patients who maintain therapy typically sustain 1522% weight loss over 2+ years, with cardiovascular and metabolic benefits continuing to accumulate
-Amyloid protein induces mitophagy-dependent ferroptosis through the CD36/PINK1/Parkin pathway leading to bloodbrain barrier destruction in Alzheimers disease